febuxostat Articles
Global rheumatology market controlled by Enbrel, Humira and Remicade
24 December 2012
Majority of gout patients on uric acid lowering therapy fail to achieve control of serum urate levels report
10 June 2012
Takeda to acquire URL Pharma for $800 million
12 April 2012
Menarini extends febuxostat accord to more regions
12 April 2012
New study highlights changes in the management of gout and hyperuricemia among US rheumatologists and PCPs
2 March 2010
Ipsen grants Menarini exclusive European rights to Adenuric in up to 132 million-euro deal
20 October 2009
Teijin licenses febuxostat to Astellas in Taiwan
14 May 2009
Japan stock market week to March 16, 2009
23 March 2009
Japan stock market week to Feb 16, 2009
23 February 2009
Takeda/Teijin gain US OK for new gout drug
23 February 2009
FDA delays decision on Takeda's febuxostat
26 January 2009
NICE recommends Ipsen drug for gout treatment
12 January 2009
Japan stock market week to March 24, 2008
31 March 2008
Ipsen's Adenuric gets nod from CHMP
3 March 2008
Japan stock market week to Oct 22, 2007
29 October 2007
EMEA validates Ipsen's febuxostat marketing application
9 October 2006
Japan stock market week to Jan 30, 2006
6 February 2006
Japan stock market three weeks to January 3
10 January 2005
Showing 1-24 of 24 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
